Hirofumi Uehara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hirofumi Uehara has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mingyon Mun
Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Tokyo 135-8550, Japan
2 shared publications - Yukinori Sakao
Department of Surgery, Teikyo University School of Medicine, Tokyo 173-8605, Japan
2 shared publications A. Tsuruoka
1 shared publicationAtsushi Watanabe
Department of Thoracic Surgery, Sapporo Medical University School of Medicine and Hospital, Sapporo, Hokkaido, Japan
1 shared publication- Haruhiko Kondo
Department of Thoracic Surgery and Thyroid Surgery, Kyorin University School of Medicine, Tokyo 181-8611, Japan
1 shared publication - Haruhisa Matsuguma
Division of Thoracic Surgery, Tochigi Cancer Center, Utsunomiya 320-0834, Japan
1 shared publication
Latest Publications
- Open Access
Survival after Lung Metastasectomy from Urothelial Carcinoma: A Multi-Institutional Database Study
Background/objectives: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies. In this study, we aimed to assess the prognostic outcomes of excising pulmonary metastases from urothelial carcinoma. Methods: In this study, we utilized data from the Metastatic Lung Tumor Study Group of Japan database, a multi-institutional prospective database of pulmonary metastasectomies. We examined the data of patients who had undergone pulmonary metastasectomy for urothelial carcinoma between 1985 and 2021. Exclusion criteria included insufficient clinical information and follow-up of <3 months. Results: The study cohort comprised 100 patients (63 bladder cancer, 37 renal pelvic and ureteral cancer), with a median follow-up of 34 months. There were 70 male and 30 female patients of average age 66.5 ± 10.4 years at lung metastasectomy. The median interval from treatment of the primary lesion to metastasectomy was 19 months and the maximum tumor diameter was 21 ± 15 mm. Three- and five-year overall survival rates were 69% and 59%, respectively. Three- and five-year disease-free survival rates were 56% and 46%, respectively. Multivariate analysis identified larger tumor diameter (hazard ratio: 1.62, 95% confidence interval: 1.21–2.17) and distant metastases at the time of treatment of the primary cancer (hazard ratio: 4.23; 95% confidence interval: 1.54–11.6) as significant adverse prognostic factors for overall survival. Conclusions: To our knowledge, this is the largest published case series of pulmonary resection for metastatic urothelial carcinoma, providing benchmark data for the assessment of long-term outcomes of this rare entity.
Open AccessSurvival after Lung Metastasectomy from Urothelial Carcinoma: A Multi-Institutional Database Study
Background/objectives: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies. In this study, we aimed to assess the prognostic outcomes of excising pulmonary metastases from urothelial carcinoma. Methods: In this study, we utilized data from the Metastatic Lung Tumor Study Group of Japan database, a multi-institutional prospective database of pulmonary metastasectomies. We examined the data of patients who had undergone pulmonary metastasectomy for urothelial carcinoma between 1985 and 2021. Exclusion criteria included insufficient clinical information and follow-up of <3 months. Results: The study cohort comprised 100 patients (63 bladder cancer, 37 renal pelvic and ureteral cancer), with a median follow-up of 34 months. There were 70 male and 30 female patients of average age 66.5 ± 10.4 years at lung metastasectomy. The median interval from treatment of the primary lesion to metastasectomy was 19 months and the maximum tumor diameter was 21 ± 15 mm. Three- and five-year overall survival rates were 69% and 59%, respectively. Three- and five-year disease-free survival rates were 56% and 46%, respectively. Multivariate analysis identified larger tumor diameter (hazard ratio: 1.62, 95% confidence interval: 1.21–2.17) and distant metastases at the time of treatment of the primary cancer (hazard ratio: 4.23; 95% confidence interval: 1.54–11.6) as significant adverse prognostic factors for overall survival. Conclusions: To our knowledge, this is the largest published case series of pulmonary resection for metastatic urothelial carcinoma, providing benchmark data for the assessment of long-term outcomes of this rare entity.
- 1 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (3) , e185-e187
Salvage Surgery for Bronchopleural Fistula Due to Durvalumab and Chemoradiation
- 1 September 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (3) , e185-e187
Salvage Surgery for Bronchopleural Fistula Due to Durvalumab and Chemoradiation
- Open Access
- 1 January 2008
- Published by Japan Lung Cancer Society in Haigan
- Vol. 48 (4) , 266-272
Validity of Omission of Subcarinal Lymph Node Dissection in Patients with Cancer of the Right Upper Lobe Or Left Upper Division of the Lung
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。
- 1 January 2008
- Published by Japan Lung Cancer Society in Haigan
- Vol. 48 (4) , 266-272
Open AccessValidity of Omission of Subcarinal Lymph Node Dissection in Patients with Cancer of the Right Upper Lobe Or Left Upper Division of the Lung
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。